The National Stock Exchange of India has finally received approval to prepare for its IPO, ending a nearly 10-year wait. The move comes after regulatory issues, including a 2019 market ban and a $141 million settlement proposal, stalled its plans.
Finding specialized tech workers remains brutally difficult for most companies. New data shows the core skills needed are about to shift dramatically, complicating hiring efforts even further.
Securing funding for a climate tech startup is a unique challenge. According to a VC with deep experience, founders need a specific playbook that goes beyond a great idea.
HashiCorp co-founder Mitchell Hashimoto sparked a major debate on X by advising workers to stay off their phones and find menial tasks like sweeping floors. His comments, drawing from his seven years in retail, were met with pushback about pay, culture, and slack capacity. The conversation highlight
Mos Health has secured pre-Seed funding to build an AI-powered preventive health platform. It combines app-based protocols with proprietary supplements, launching first in the U.S. through a B2B2C model.
York Space Systems, a key Pentagon satellite supplier, began trading on the NYSE. The IPO values the company at $4.75 billion as it aims to boost production for military space programs.
According to TechCrunch, SpaceX is lining up Wall Street banks for a potential 2026 public offering. The company’s recent tender offer valued it at $800 billion, but the IPO could target a jaw-dropping $1.5 trillion. This move is expected to trigger a cascade of other unicorn IPOs.
ZOLLHOF – Tech Incubator has launched its own venture capital arm, ZOHO.VC, with a target fund of €10 million. The fund has already secured 70% of its capital at its first close, ten months ahead of schedule. It will focus on pre-Seed and Seed-stage technology startups.
Most founders obsess over systems and tech, but growth is a people game. The secret isn’t just finding skills; it’s finding the right mindsets and making them stick from day one.
CRISPR pioneer Jennifer Doudna has co-founded a startup, Aurora Therapeutics, to create tailored gene-editing treatments for rare diseases. Their strategy hinges on a new FDA regulatory pathway that could dramatically speed up approvals.
